Display options
Cite
Scheifele DW, Bjornson GL, Meekison WG, et al. Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants. Can J Infect Dis. 1994;5(2):75-81doi: 10.1155/1994/479313.
Scheifele, D. W., Bjornson, G. L., Meekison, W. G., Guasparini, R., & Mitchell, L. A. (1994). Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 5(2), 75-81. https://doi.org/10.1155/1994/479313
Scheifele, D W, et al. "Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants." The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 5,2 (1994): 75-81. doi: https://doi.org/10.1155/1994/479313
Scheifele DW, Bjornson GL, Meekison WG, Guasparini R, Mitchell LA. Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants. Can J Infect Dis. 1994 Mar;5(2):75-81. doi: 10.1155/1994/479313. PMID: 22451769; PMCID: PMC3307411.
Copy Download .nbib Format: NLM
Share it on

Can J Infect Dis. 1994 Mar;5(2):75-81. doi: 10.1155/1994/479313.

Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses

D W Scheifele, G L Bjornson, W G Meekison, R Guasparini, L A Mitchell

Affiliations

  1. Vaccine Evaluation Center, BC's Children's Hospital and the University of British Columbia, Vancouver.

PMID: 22451769 PMCID: PMC3307411 DOI: 10.1155/1994/479313

Abstract

OBJECTIVE: To assess adverse effects and immune responses with a three-dose series of Haemophilus influenzae type b meningococcal protein conjugate (PedvaxHIB or Hib.OMP) vaccine, including any immunological response alterations from concurrent administration with routine vaccines for infants.

DESIGN: Randomized, controlled trial with treatment group crossover for dose 3.

SETTING: Two public health units near Vancouver.

PARTICIPANTS: One hundred and ten healthy infants eight to 14 weeks old were enrolled; 105 completed the study (95%).

INTERVENTIONS: All participants received two doses of diphtheria-pertussis-tetanus (dpt) vaccine (at two and four months of age) and one dose of measles-mumps-rubella (mmr) vaccine at 12 months. In each instance, Hib.OMP was given either concurrently in another limb or after a delay of two weeks (after dpt) or four weeks (after mmr).

MAIN OUTCOME MEASURES: Adverse effects, particularly fever and local erythema, were monitored by parents for 72 h after each dose of Hib.OMP vaccine. Five blood samples were taken at prescribed intervals to assess responses to each dose of Hib.OMP and to selected other vaccine antigens.

MAIN RESULTS: Follow-up was obtained after all 322 doses of Hib.OMP. Local adverse effects were infrequent and mild: 13% had redness, 17% tenderness. Systemic effects in those given Hib.OMP alone included fever in 8%, irritability in 29%. Anti-polyribose-ribitol phosphate (prp) responses to Hib.OMP were not impaired by coadministration with dpt or mmr vaccines, nor were tetanus or diphtheria antitoxin levels or rubella or measles response rates affected. After two doses of Hib.OMP, 92% were seropositive and 64% had greater than 1.0 μg/mL of anti-prp. After three doses, 100% were seropositive and 82% exceeded 1.0 μg/mL.

CONCLUSION: Hib.OMP vaccine was well tolerated, immunogenic and compatible with vaccines routinely given to infants in Canada.

Keywords: Haemophilus influenzae type b; Meningococcal protein conjugate vaccine; Prevention; Vaccine

References

  1. CMAJ. 1988 Oct 15;139(8):743-7 - PubMed
  2. J Pediatr. 1992 Aug;121(2):187-94 - PubMed
  3. N Engl J Med. 1991 Jun 20;324(25):1767-72 - PubMed
  4. N Engl J Med. 1990 Nov 15;323(20):1381-7 - PubMed
  5. JAMA. 1992 Mar 18;267(11):1489-94 - PubMed
  6. Pediatrics. 1977 Nov;60(5):730-7 - PubMed
  7. J Infect Dis. 1982 Aug;146(2):249-54 - PubMed
  8. MMWR Morb Mortal Wkly Rep. 1992 Nov 20;41(46):878-9 - PubMed
  9. J Infect Dis. 1990 Nov;162(5):1185-8 - PubMed
  10. J Infect Dis. 1993 May;167(5):1210-2 - PubMed
  11. Pediatrics. 1990 Apr;85(4 Pt 2):676-81 - PubMed
  12. Vaccine. 1991 Jun;9 Suppl:S38-41; discussion S42-3 - PubMed
  13. J Pediatr. 1992 Sep;121(3):355-62 - PubMed
  14. Pediatr Infect Dis J. 1987 Aug;6(8):779-82 - PubMed
  15. J Pediatr. 1988 Oct;113(4):621-31 - PubMed
  16. Pediatrics. 1987 Aug;80(2):283-7 - PubMed
  17. Pediatr Infect Dis J. 1991 Feb;10(2):97-104 - PubMed
  18. J Infect Dis. 1992 Jun;165 Suppl 1:S129-33 - PubMed
  19. Pediatrics. 1990 Apr;85(4 Pt 2):682-9 - PubMed
  20. J Infect Dis. 1990 Jul;162(1):163-71 - PubMed

Publication Types